title: Clinical penetrance of C282Y homozygous HFE haemochromatosis.
abstract: The prevalence of the C282Y homozygous HFE genotype is high, approximately 1 in 200 in populations of Anglo-Celtic descent, and most authorities assumed this mutation would have a high clinical penetrance. Recent studies report the clinical penetrance of C282Y homozygous hereditary haemochromatosis is much lower than its prevalence, with possibly less than 5% developing clinical disease, although there is lack of consensus on a precise estimate. This review discusses reasons for this paradigm shift, including controversy on various definitions of clinical penetrance. It is inescapable that there are pronounced variations in clinical penetrance, and that certain C282Y homozygous individuals will not develop the clinical phenotype. This has prompted a search for modifier gene mutations amongst iron-metabolism genes, especially the known non- HFE haemochromatosis genes, and for possible environmental factors which might explain the observed variation in clinical penetrance.
authors.affiliation: Department of Clinical Biochemistry, PathCentre, University of Western Australia, Nedlands, WA, Australia. ric.rossi@health.wa.gov.au
authors.forename: Enrico
authors.initials: E
authors.lastname: Rossi
authors.forename: Gary P
authors.initials: GP
authors.lastname: Jeffrey